Skip to content
Screener

BioMarin Pharmaceuticals BMRN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-59.3%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1K-100.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$3.15M+4,745%
Regenxbio logo
RegenxbioRGNX
$19.35M+24,712%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$22.59M—

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The source filing: BioMarin Pharmaceuticals’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 12:30 PM EST
Fiscal year
FY2025
Accession
0001048477-26-000004
Line item202520242023
Other—1,141—
Net cash provided by (used in) investing activities(414,242)136,491(111,244)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of awards under equity incentive plans14,46049,27769,353
Taxes paid related to net share settlement of equity awards(55,965)(77,560)(76,319)
Repayments of convertible debt—(494,987)—
Other(889)(3,177)(11,761)
Net cash used in financing activities(42,394)(526,447)(18,727)

Item 16. Form 10-K Summary

FAQ

What is BioMarin Pharmaceuticals's stock issuance proceeds?
BioMarin Pharmaceuticals (BMRN) reported stock issuance proceeds of $6.75M in Q4 2025.
How has BioMarin Pharmaceuticals's stock issuance proceeds changed year-over-year?
BioMarin Pharmaceuticals's stock issuance proceeds decreased by 14.2% year-over-year, from $7.86M to $6.75M.
What is the long-term trend for BioMarin Pharmaceuticals's stock issuance proceeds?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's stock issuance proceeds has grown at a -26.4% compound annual growth rate (CAGR), from $49.19M to $14.46M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about BioMarin Pharmaceuticals's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude